Literature DB >> 3024562

Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir.

A Larsson, K Stenberg, A C Ericson, U Haglund, W A Yisak, N G Johansson, B Oberg, R Datema.   

Abstract

9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine (3HM-HBG), (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine ([+/-]2HM-HBG), and cis-9-(4-hydroxy-2-butenyl)guanine (2EN-HBG), new acyclic guanosine analogs structurally related to buciclovir (BCV [(R)-9-(3,4-dihydroxybutyl)guanine]), were evaluated in parallel with buciclovir as anti-herpes simplex virus (HSV) agents. In cell cultures, replication of different strains of HSV type 1 (HSV-1) and HSV-2 was inhibited at nontoxic drug concentrations. The concentrations giving 50% inhibition of plaque formation were, however, dependent on virus strain and cell type. In most cell types, the order of activity against HSV-1 strains was 3HM-HBG greater than (+/-)2HM-HBG greater than BCV greater than 2EN-HBG, whereas the drugs showed an approximately equivalent activity against HSV-2 strains in different cells. The cytotoxic effects of the drugs were also cell type dependent, the order of activity being BCV greater than 3HM-HBG = (+/-)2HM-HBG greater than 2EN-HBG. At growth-inhibitory concentrations, the guanosine analogs BCV, 3HM-HBG, and (+/-)2HM-HBG showed clastogenic effects in human lymphocytes, mainly because of the induction of chromatid breaks. When evaluated for their anti-HSV effects in systemic HSV-1 infections in mice, the order of activity was BCV = 3HM-HBG greater than (+/-)2HM-HBG greater than 2EN-HBG, and in mice infected systemically with HSV-2, only BCV and 3HM-HBG showed efficacy. The differences between efficacy in vitro and in vivo could be explained in part by differences in kinetics of the drugs in mouse plasma, as the more efficacious drugs, BCV and 3HM-HBG, showed lower clearances and longer half-lives than the less efficacious ones, (+/-)2HM-HBG and 2EN-HBG. When used topically against a cutaneous HSV-1 infection in guinea pigs, 3HM-HBG showed an effect equivalent to that of BCV, whereas (+/-)2HM-HBG and 2EN-HBG were inactive. Mechanistically, the guanosine analogs were characterized by a high affinity for the viral thymidine kinase and a low affinity fo a cellular thymidine kinase and by their inhibition of viral DNA synthesis in infected cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024562      PMCID: PMC176488          DOI: 10.1128/AAC.30.4.598

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Phosphorylation of four acyclic guanosine analogs by herpes simplex virus type 2 thymidine kinase.

Authors:  A Larsson; P Z Tao
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

2.  Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U.

Authors:  M H St Clair; W H Miller; R L Miller; C U Lambe; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

3.  Preclinical toxicology studies with acyclovir: genetic toxicity tests.

Authors:  D Clive; N T Turner; J Hozier; A G Batson; W E Tucker
Journal:  Fundam Appl Toxicol       Date:  1983 Nov-Dec

4.  Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis.

Authors:  H Gadler; A Larsson; E Sølver
Journal:  Antiviral Res       Date:  1984-04       Impact factor: 5.970

5.  Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function.

Authors:  D Derse; Y C Cheng; P A Furman; M H St Clair; G B Elion
Journal:  J Biol Chem       Date:  1981-11-25       Impact factor: 5.157

6.  A comparison of the antiviral agents 2'-nor-2'-deoxyguanosine and acyclovir: uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates.

Authors:  J Germershausen; R Bostedor; A K Field; H Perry; R Liou; H Bull; R L Tolman; J D Karkas
Journal:  Biochem Biophys Res Commun       Date:  1983-10-31       Impact factor: 3.575

7.  Antiherpetic activity and mechanism of action of 9-(4-hydroxybutyl)guanine.

Authors:  A Larsson; S Alenius; N G Johansson; B Oberg
Journal:  Antiviral Res       Date:  1983-08       Impact factor: 5.970

8.  Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells.

Authors:  Y C Cheng; S P Grill; G E Dutschman; K Nakayama; K F Bastow
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

9.  Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate.

Authors:  K B Frank; J F Chiou; Y C Cheng
Journal:  J Biol Chem       Date:  1984-02-10       Impact factor: 5.157

10.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.

Authors:  A K Field; M E Davies; C DeWitt; H C Perry; R Liou; J Germershausen; J D Karkas; W T Ashton; D B Johnston; R L Tolman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

View more
  18 in total

Review 1.  Screening for new agents.

Authors:  B Oberg; L Vrang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.

Authors:  M R Boyd; T H Bacon; D Sutton
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir.

Authors:  Tatsuo Suzutani; Ken Ishioka; Erik De Clercq; Kei Ishibashi; Hisatoshi Kaneko; Toshihiko Kira; Koh-Ichi Hashimoto; Masahiro Ogasawara; Katsuki Ohtani; Nobutaka Wakamiya; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.

Authors:  Federico Focher; Andrea Lossani; Annalisa Verri; Silvio Spadari; Andrew Maioli; Joseph J Gambino; George E Wright; Richard Eberle; Darla H Black; Peter Medveczky; Maria Medveczky; David Shugar
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

Review 5.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.

Authors:  N Ono; S Iwayama; K Suzuki; T Sekiyama; H Nakazawa; T Tsuji; M Okunishi; T Daikoku; Y Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.

Authors:  M R Boyd; T H Bacon; D Sutton; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

8.  In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2.

Authors:  A Weinberg; B J Bate; H B Masters; S A Schneider; J C Clark; C G Wren; J A Allaman; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

9.  Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16.

Authors:  D Sutton; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.

Authors:  D M Lake-Bakaar; G Abele; B Lindborg; K F Soike; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.